Supplemental Evidence and Data Request on Management of Suicidal Thoughts and Behaviors in Youth, 44981-44983 [2024-11197]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 100 / Wednesday, May 22, 2024 / Notices
Government-wide Policy and the
Federal Acquisition Service and is
posted on https://www.gsa.gov/policyregulations/regulations/federal-travelregulation/ftr-and-related-files#Travel
PerDiemBulletins.
DATES: This bulletin is applicable after
April 15, 2024.
FOR FURTHER INFORMATION CONTACT:
Ryan Edelstein, ETSNext Program
Director, GSA, Office of Travel,
Employee Relocation and
Transportation at 703–835–2830.
SUPPLEMENTARY INFORMATION:
Background
ETSNext is the next generation
governmentwide travel & expense
solution being acquired by GSA. It is a
mandatory program and GSA has
responsibility through the Office of
Governmentwide Policy, FAS Program
Management and Governmentwide
Category Management to provide this
ETSNext solution.
The Bulletin provides immediate,
actionable and practical steps agencies
should take now to prepare for the
transition to ETSNext. Agency actions
include:
• Engaging with GSA to determine
budgets and timelines for your agency’s
transition to ETSNext.
• Preparing for and prioritizing
financial management (FM) systems
integration with ETSNext.
• Executing a memorandum of
understanding (MOU) with GSA that
will memorialize both GSA’s and
agencies’ understanding that certain
tasks must be completed in accordance
with a defined schedule to ensure a
successful transition to ETSNext and the
utilization of ETSNext for the life of the
contract.
Timothy Burke,
Executive Director, GSA Office of Travel,
Employee Relocation and Transportation.
[FR Doc. 2024–11170 Filed 5–21–24; 8:45 am]
BILLING CODE 6820–V1–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
khammond on DSKJM1Z7X2PROD with NOTICES
Agency for Healthcare Research and
Quality
Supplemental Evidence and Data
Request on Management of Suicidal
Thoughts and Behaviors in Youth
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for supplemental
evidence and data submission.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
SUMMARY:
VerDate Sep<11>2014
17:06 May 21, 2024
Jkt 262001
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
Management of Suicidal Thoughts and
Behaviors in Youth, which is currently
being conducted by the AHRQ’s
Evidence-based Practice Centers (EPC)
Program. Access to published and
unpublished pertinent scientific
information will improve the quality of
this review.
DATES: Submission Deadline on or
before June 21, 2024.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
Attn: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers
Lane, Mail Stop 06E77D, Rockville,
MD 20857
FOR FURTHER INFORMATION CONTACT:
Kelly Carper, Telephone: 301–427–1656
or email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for Management of Suicidal
Thoughts and Behaviors in Youth.
AHRQ is conducting this review
pursuant to Section 902 of the Public
Health Service Act, 42 U.S.C. 299a.
The EPC Program is dedicated to
identifying as many studies as possible
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on Management of Suicidal
Thoughts and Behaviors in Youth. The
entire research protocol is available
online at: https://effectivehealthcare.
ahrq.gov/products/suicidal-thoughtsyouth/protocol.
This is to notify the public that the
EPC Program would find the following
information on Management of Suicidal
Thoughts and Behaviors in Youth
helpful:
D A list of completed studies that
your organization has sponsored for this
topic. In the list, please indicate
whether results are available on
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
44981
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements, if relevant: study number,
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, primary and secondary
outcomes, baseline characteristics,
number of patients screened/eligible/
enrolled/lost to follow-up/withdrawn/
analyzed, effectiveness/efficacy, and
safety results.
D A list of ongoing studies that your
organization has sponsored for this
topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including, if relevant, a study
number, the study period, design,
methodology, indication and diagnosis,
proper use instructions, inclusion and
exclusion criteria, and primary and
secondary outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this topic and an index
outlining the relevant information in
each submitted file.
Your contribution is very beneficial to
the Program. Materials submitted must
be publicly available or able to be made
public. Materials that are considered
confidential; marketing materials; study
types not included in the review; or
information on topics not included in
the review cannot be used by the EPC
Program. This is a voluntary request for
information, and all costs for complying
with this request must be borne by the
submitter.
The draft of this review will be posted
on AHRQ’s EPC Program website and
available for public comment for a
period of 4 weeks. If you would like to
be notified when the draft is posted,
please sign up for the email list at:
https://effectivehealthcare.ahrq.gov/
email-updates.
The review will answer the following
questions. This information is provided
as background. AHRQ is not requesting
that the public provide answers to these
questions.
Key Questions (KQ)
KQ 1. For youth, what are the
effectiveness, comparative effectiveness,
and harms of treatments for suicidal
thoughts and behaviors?
(a) What are the components of
effective psychosocial treatments (e.g.,
frequency or intensity of therapy and/or
aspects of the therapeutic modality)?
(b) How do social determinants of
health, racism and disparities, care
E:\FR\FM\22MYN1.SGM
22MYN1
44982
Federal Register / Vol. 89, No. 100 / Wednesday, May 22, 2024 / Notices
delivery methods, patient demographics
and psychiatric or developmental cooccurring conditions affect outcomes?
PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, AND SETTING)
PICOTS elements
Inclusion criteria
Population ..................................
• Ages 5–24 years who have a heightened risk for suicide,
including—
Æ Those who have suicidal ideation (i.e., thinking about or
planning suicide) with or without self-injurious behaviors
(i.e., suicide attempt or self-injurious behavior, including
self-directed deliberate injury or potential for injury).
Æ Those who have made suicide attempts in the absence
of known suicidal ideation.
Æ Those who have a recent hospital discharge for mental
health treatment.
Æ Those who have shown command hallucination (i.e., auditory hallucinations that instruct a patient to act in specific manners) or intense stress/distress.
Æ Those who are identified as having heightened risk by
PHQ–9, C–SSRS, or ASQ.
Æ Those who are from racial/ethnic minority groups known
to have increased risk of suicide.
Æ Those who are from the LGBTQ+ community ..................
Æ Those who have/had exposure to high crime/violence .....
• An intervention aimed to reduce suicidal and thoughts behaviors—
Æ Psychosocial interventions .................................................
Æ Pharmacological therapy ...................................................
Æ Neurotherapeutics and emerging therapies ......................
Æ Combination therapies of the above ..................................
• Treatment as usual ................................................................
• Another psychosocial intervention .........................................
• Another pharmacological therapy ..........................................
• Combination therapies of the above ......................................
• Suicidal behaviors (e.g., suicidal attempts, self-harm with
suicidal intent, self-harm without suicidal intent).
• Suicidal ideation .....................................................................
• Measures of severity of suicide ideation and intent (e.g., C–
SSRS, Sheehan STS, SIQ).
• Deaths by suicide ..................................................................
• Hospitalizations for suicidal thoughts or behaviors ...............
• Emergency department visits for suicidal thoughts or behaviors.
• Measures of psychological functioning after receiving an
intervention targeting suicidal behaviors and thoughts (e.g., depression, anxiety, stress, coping, sense of purpose, agency,
burdensomeness, thwarted belonging as reported by child and
caregivers, quality of life.
• School outcomes [e.g., functioning in school, attendance,
drop-out]).
• Adverse events, including study withdrawals ........................
• At the end of intervention and at the end of followup ...........
• Any (e.g., outpatient, inpatient, emergency department) ......
• RCTs ......................................................................................
• Comparative observational studies ........................................
• Before—after studies .............................................................
• Relevant systematic reviews, or meta-analyses (used for
identifying additional studies).
• Delivery methods (e.g., telehealth, in-home treatment,
school-based intervention, clinic).
• Age group (5–13 years, 14–17 years, and 18–24 years) .....
• Gender/gender identity ..........................................................
• Race/ethnicity .........................................................................
• History of trauma ...................................................................
• Experience of racial/ethnic discrimination and
marginalization.
• Sexual orientation ..................................................................
• Co-occurring conditions (e.g., MDD, bipolar disorder, mood
disorders, substance use disorders, eating disorders,
posttraumatic stress disorder, autism, intellectual/developmental
disabilities, other special needs),.
• Intervention objectives (i.e., addressing suicidal thoughts
vs. suicidal behaviors; ongoing treatments following crisis care
vs. crisis care).
• Clinical settings (e.g., outpatient, inpatient, residential,
emergency department).
• Timing of outcome assessment (e.g., long-term outcome
assessment, short-term outcome assessment).
• Social determinants of health (e.g., access to mental
healthcare, access to housing, poverty, exposure to violence/
crime).
Interventions ..............................
Comparators ..............................
Outcomes ..................................
Timing ........................................
Settings ......................................
Study design ..............................
khammond on DSKJM1Z7X2PROD with NOTICES
Subgroup analysis .....................
VerDate Sep<11>2014
17:06 May 21, 2024
Jkt 262001
PO 00000
Frm 00027
Fmt 4703
Exclusion criteria
Sfmt 4703
• Animals.
• Adults aged >25 years.
• Complementary or integrative health interventions (e.g.,
light therapy, supplements).
• None.
• None.
• None.
• None.
• In vitro studies.
• Nonoriginal studies (e.g., narrative reviews, editorials, letters, or erratum).
• Cross-sectional (i.e., nonlongitudinal) studies.
• None.
E:\FR\FM\22MYN1.SGM
22MYN1
Federal Register / Vol. 89, No. 100 / Wednesday, May 22, 2024 / Notices
44983
PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, AND SETTING)—Continued
PICOTS elements
Publications ...............................
Inclusion criteria
Exclusion criteria
• Full-text peer-reviewed studies published in English ............
• Studies published after the year 2000 ...................................
• Non-English language studies.
• Conference abstracts.
Abbreviations: ASQ = Ask Suicide-Screening Questions; C–SSRS = Columbia Suicide Severity Rating Scale; LGBTQ+ = Lesbian Gay Bisexual Transgender
Queer/Questioning Plus/Others; MDD = major depressive disorder; PHQ–9 = Patient Health Questionnaire–9; RCT = randomized controlled trial; Sheehan STS =
Sheehan Suicidality Tracking Scale; SIQ = Suicidal Ideation Questionnaire.
Dated: May 16, 2024.
Mamatha Pancholi,
Deputy Director.
Proposed Project
Implementation and Testing of
Diagnostic Safety Resources
[FR Doc. 2024–11197 Filed 5–21–24; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice.
AGENCY:
This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve the proposed
information collection project
‘‘Implementation and Testing of
Diagnostic Safety Resources.’’ This
proposed information collection was
previously published in the Federal
Register on March 7th, 2024 and
allowed 60 days for public comment.
AHRQ received no substantive
comments from members of the public.
The purpose of this notice is to allow an
additional 30 days for public comment.
DATES: Comments on this notice must be
received by June 21, 2024.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Copies of the proposed
collection plans, data collection
instruments, and specific details on the
estimated burden can be obtained from
the AHRQ Reports Clearance Officer.
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427–1477, or by
email REPORTSCLEARANCEOFFICER@
ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:06 May 21, 2024
Jkt 262001
Patient safety is a pillar of the Agency
for Healthcare Research and Quality’s
(AHRQ’s) mission to support the highest
quality healthcare. While progress has
been made in many areas of patient
safety, the field of diagnostic safety has
emerged as a particular area of concern.
It is estimated that every person in the
United States will experience a
diagnostic error in their lifetime
(Institute of Medicine, 2015) which can
lead to inappropriate, delayed, or
withheld treatment and ultimately poor
health outcomes, distress, and increased
costs. Diagnostic errors can occur for
many reasons: lack of meaningful
engagement between clinicians,
patients, and families; a fragmented
healthcare system not designed to
account for an increasingly complex
diagnostic process; minimal (if any)
feedback to clinicians about their
diagnostic performance; and a culture
that does not always support
transparent disclosure of diagnostic
errors (Institute of Medicine, 2015).
Leaders in diagnostic excellence suggest
that multi-pronged efforts are needed to
address this complex problem and go
beyond individual behaviors to systemlevel changes and empowering patients
to engage in their care (Institute of
Medicine, 2015; Henriksen, et al., 2017).
Improving diagnostic safety and
quality is an AHRQ priority. In
recognition of the multifaceted
approach needed to effectively advance
diagnostic safety, AHRQ recently
supported the development of three
tools to prevent diagnostic errors and
have prioritized these tools for
implementation and testing. These
resources vary in the types of
stakeholders they target, a critical
advancement in our approach to
diagnostic excellence.
• Calibrate Dx. This tool, targeted to
individual clinicians, invites users to
select a topic or condition, review
diagnostic performance on a sample of
cases for insights and learning
opportunities, and debrief with a peer.
This resource will be tested in all
settings where clinicians are involved in
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
the diagnostic process, including both
inpatient and ambulatory settings.
• Measure Dx. This tool supports
healthcare organizations in building
sustainable teams for improving
diagnostic excellence, identifying
current capacity gaps, engaging in
measurement strategies as part of a
systematic approach to reviewing
available data, and translating findings
into learning opportunities. This
resource will be tested in both inpatient
and ambulatory settings; it is expected
to be implemented more commonly in
inpatient settings.
• Toolkit for Engaging Patients to
Improve Diagnostic Safety (Patient
Toolkit). This tool prepares patients,
families, and health professionals to
work together as partners to improve
diagnostic safety; encourages patients to
prepare for visits; and encourages
providers to listen for 60 seconds before
interrupting the patient. This resource
will be tested in ambulatory settings
only.
The goal of this research is to
implement and test these three
diagnostic safety resources to identify
specific ways in which each resource
can be used to maximize its value. For
each resource the following will be
examined:
(1) Feasibility of implementation—
barriers, facilitators, success factors, and
time needed for implementation
(2) Level of adoption—number and
type of clinicians aware of and/or using
the resource, number of organizational
leaders endorsing the resource
(3) Effectiveness of the resource—
number of diagnostic safety events
(Measure Dx and Patient Toolkit),
clinician self-efficacy for diagnostic
decision-making (Calibrate Dx)
(4) Maintenance and sustainability—
the number and type of patient safety
processes in place, barriers and
facilitators to maintenance and
sustainability
This project will implement and test
these three diagnostic safety resources
across a minimum of 150 sites to up to
219 sites (i.e., 50 to 73 sites per
resource). An Implementation and
Testing period for each resource will
last 12 months, with Calibrate Dx
starting implementation first and
Measure Dx and the Toolkit for
E:\FR\FM\22MYN1.SGM
22MYN1
]]>Agencies
[Federal Register Volume 89, Number 100 (Wednesday, May 22, 2024)]
[Notices]
[Pages 44981-44983]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11197]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Supplemental Evidence and Data Request on Management of Suicidal
Thoughts and Behaviors in Youth
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for supplemental evidence and data submission.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking scientific information submissions from the public. Scientific
information is being solicited to inform our review on Management of
Suicidal Thoughts and Behaviors in Youth, which is currently being
conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program.
Access to published and unpublished pertinent scientific information
will improve the quality of this review.
DATES: Submission Deadline on or before June 21, 2024.
ADDRESSES:
Email submissions: [email protected].
Print submissions:
Mailing Address: Center for Evidence and Practice Improvement, Agency
for Healthcare Research and Quality, Attn: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857
Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice
Improvement, Agency for Healthcare Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD
20857
FOR FURTHER INFORMATION CONTACT: Kelly Carper, Telephone: 301-427-1656
or email: [email protected].
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and
Quality has commissioned the Evidence-based Practice Centers (EPC)
Program to complete a review of the evidence for Management of Suicidal
Thoughts and Behaviors in Youth. AHRQ is conducting this review
pursuant to Section 902 of the Public Health Service Act, 42 U.S.C.
299a.
The EPC Program is dedicated to identifying as many studies as
possible that are relevant to the questions for each of its reviews. In
order to do so, we are supplementing the usual manual and electronic
database searches of the literature by requesting information from the
public (e.g., details of studies conducted). We are looking for studies
that report on Management of Suicidal Thoughts and Behaviors in Youth.
The entire research protocol is available online at: https://effectivehealthcare.ahrq.gov/products/suicidal-thoughts-youth/protocol.
This is to notify the public that the EPC Program would find the
following information on Management of Suicidal Thoughts and Behaviors
in Youth helpful:
[ssquf] A list of completed studies that your organization has
sponsored for this topic. In the list, please indicate whether results
are available on ClinicalTrials.gov along with the ClinicalTrials.gov
trial number.
[ssquf] For completed studies that do not have results on
ClinicalTrials.gov, a summary, including the following elements, if
relevant: study number, study period, design, methodology, indication
and diagnosis, proper use instructions, inclusion and exclusion
criteria, primary and secondary outcomes, baseline characteristics,
number of patients screened/eligible/enrolled/lost to follow-up/
withdrawn/analyzed, effectiveness/efficacy, and safety results.
[ssquf] A list of ongoing studies that your organization has
sponsored for this topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the trial is not registered, the
protocol for the study including, if relevant, a study number, the
study period, design, methodology, indication and diagnosis, proper use
instructions, inclusion and exclusion criteria, and primary and
secondary outcomes.
[ssquf] Description of whether the above studies constitute ALL
Phase II and above clinical trials sponsored by your organization for
this topic and an index outlining the relevant information in each
submitted file.
Your contribution is very beneficial to the Program. Materials
submitted must be publicly available or able to be made public.
Materials that are considered confidential; marketing materials; study
types not included in the review; or information on topics not included
in the review cannot be used by the EPC Program. This is a voluntary
request for information, and all costs for complying with this request
must be borne by the submitter.
The draft of this review will be posted on AHRQ's EPC Program
website and available for public comment for a period of 4 weeks. If
you would like to be notified when the draft is posted, please sign up
for the email list at: https://effectivehealthcare.ahrq.gov/email-updates.
The review will answer the following questions. This information is
provided as background. AHRQ is not requesting that the public provide
answers to these questions.
Key Questions (KQ)
KQ 1. For youth, what are the effectiveness, comparative
effectiveness, and harms of treatments for suicidal thoughts and
behaviors?
(a) What are the components of effective psychosocial treatments
(e.g., frequency or intensity of therapy and/or aspects of the
therapeutic modality)?
(b) How do social determinants of health, racism and disparities,
care
[[Page 44982]]
delivery methods, patient demographics and psychiatric or developmental
co-occurring conditions affect outcomes?
PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, and
Setting)
------------------------------------------------------------------------
PICOTS elements Inclusion criteria Exclusion criteria
------------------------------------------------------------------------
Population.................. Ages 5-24 Animals.
years who have a Adults aged
heightened risk for >25 years.
suicide, including--
[cir] Those who have
suicidal ideation
(i.e., thinking
about or planning
suicide) with or
without self-
injurious behaviors
(i.e., suicide
attempt or self-
injurious behavior,
including self-
directed deliberate
injury or potential
for injury).
[cir] Those who have
made suicide
attempts in the
absence of known
suicidal ideation.
[cir] Those who have
a recent hospital
discharge for
mental health
treatment.
[cir] Those who have
shown command
hallucination
(i.e., auditory
hallucinations that
instruct a patient
to act in specific
manners) or intense
stress/distress.
[cir] Those who are
identified as
having heightened
risk by PHQ-9, C-
SSRS, or ASQ.
[cir] Those who are
from racial/ethnic
minority groups
known to have
increased risk of
suicide.
[cir] Those who are
from the LGBTQ+
community.
[cir] Those who have/
had exposure to
high crime/violence.
Interventions............... An
intervention aimed Complementary or
to reduce suicidal integrative health
and thoughts interventions (e.g.,
behaviors-- light therapy,
[cir] Psychosocial supplements).
interventions.
[cir]
Pharmacological
therapy.
[cir]
Neurotherapeutics
and emerging
therapies.
[cir] Combination
therapies of the
above.
Comparators................. Treatment None.
as usual
Another
psychosocial
intervention.
Another
pharmacological
therapy.
Combination
therapies of the
above.
Outcomes.................... Suicidal None.
behaviors (e.g.,
suicidal attempts,
self-harm with
suicidal intent,
self-harm without
suicidal intent)
Suicidal
ideation.
Measures of
severity of suicide
ideation and intent
(e.g., C-SSRS,
Sheehan STS, SIQ).
Deaths by
suicide.
Hospitalizations
for suicidal
thoughts or
behaviors.
Emergency
department visits
for suicidal
thoughts or
behaviors.
Measures of
psychological
functioning after
receiving an
intervention
targeting suicidal
behaviors and
thoughts (e.g.,
depression,
anxiety, stress,
coping, sense of
purpose, agency,
burdensomeness,
thwarted belonging
as reported by
child and
caregivers, quality
of life.
School
outcomes [e.g.,
functioning in
school, attendance,
drop-out]).
Adverse
events, including
study withdrawals.
Timing...................... At the None.
end of intervention
and at the end of
followup
Settings.................... Any None.
(e.g., outpatient,
inpatient, emergency
department)
Study design................ RCTs In vitro
Comparative studies.
observational Nonoriginal
studies. studies (e.g.,
Before-- narrative reviews,
after studies. editorials,
Relevant letters, or
systematic reviews, erratum).
or meta-analyses Cross-
(used for sectional (i.e.,
identifying nonlongitudinal)
additional studies). studies.
Subgroup analysis........... Delivery None.
methods (e.g.,
telehealth, in-home
treatment, school-
based intervention,
clinic)
Age group
(5-13 years, 14-17
years, and 18-24
years).
Gender/
gender identity.
Race/
ethnicity.
History of
trauma.
Experience
of racial/ethnic
discrimination and
marginalization.
Sexual
orientation.
Co-
occurring
conditions (e.g.,
MDD, bipolar
disorder, mood
disorders,
substance use
disorders, eating
disorders,
posttraumatic
stress disorder,
autism,
intellectual/
developmental
disabilities, other
special needs),.
Intervention
objectives (i.e.,
addressing suicidal
thoughts vs.
suicidal behaviors;
ongoing treatments
following crisis
care vs. crisis
care).
Clinical
settings (e.g.,
outpatient,
inpatient,
residential,
emergency
department).
Timing of
outcome assessment
(e.g., long-term
outcome assessment,
short-term outcome
assessment).
Social
determinants of
health (e.g.,
access to mental
healthcare, access
to housing,
poverty, exposure
to violence/crime).
[[Page 44983]]
Publications................ Full-text Non-
peer-reviewed English language
studies published in studies.
English Conference
Studies abstracts.
published after the
year 2000.
------------------------------------------------------------------------
Abbreviations: ASQ = Ask Suicide-Screening Questions; C-SSRS = Columbia
Suicide Severity Rating Scale; LGBTQ+ = Lesbian Gay Bisexual
Transgender Queer/Questioning Plus/Others; MDD = major depressive
disorder; PHQ-9 = Patient Health Questionnaire-9; RCT = randomized
controlled trial; Sheehan STS = Sheehan Suicidality Tracking Scale;
SIQ = Suicidal Ideation Questionnaire.
Dated: May 16, 2024.
Mamatha Pancholi,
Deputy Director.
[FR Doc. 2024-11197 Filed 5-21-24; 8:45 am]
BILLING CODE 4160-90-P
